ReviewAnnual review of pathology2019
Opportunities for microRNAs in the Crowded Field of Cardiovascular Biomarkers.
Review in Annual review of pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Circulating angiopoietin-2 and TEK receptor tyrosine kinase-2 protein provide prognostic value in patients with acute myocardial infarction.BMC cardiovascular disorders · 2026Article
- The European BestAgeing Study on microRNA candidates reveals distinct signatures with diagnostic and prognostic potential in cardiovascular disease.BMC medicine · 2025Article
- Circulating miRNA-486 as a novel diagnostic biomarker for right ventricular remodeling.Frontiers in cardiovascular medicine · 2025Article
- miR-29b-1-5p exacerbates myocardial injury induced by sepsis in a mouse model by targeting TERF2.Acta biochimica et biophysica Sinica · 2024Article
- MicroRNAs in Myocarditis-Review of the Preclinical In Vivo Trials.Biomedicines · 2023Review
- Advancing Precision Medicine in Myocarditis: Current Status and Future Perspectives in Endomyocardial Biopsy-Based Diagnostics and Therapeutic Approaches.Journal of clinical medicine · 2023Review
- The Effects of MicroRNAs in the Development of Heart Failure.Current cardiology reports · 2023Review
- Clinical Significance of MicroRNAs, Long Non-Coding RNAs, and CircRNAs in Cardiovascular Diseases.Cells · 2023Review
- Precision Medicine and the future of Cardiovascular Diseases: A Clinically Oriented Comprehensive Review.Journal of clinical medicine · 2023Review
- Research progress of non-coding RNA in atrial fibrillation.Frontiers in cardiovascular medicine · 2023Review
- microRNAs as biomarkers of risk of major adverse cardiovascular events in atrial fibrillation.Frontiers in cardiovascular medicine · 2023Review
- MiR-199a-3p promotes repair of myocardial infarction by targeting NACC2.International journal of clinical and experimental pathology · 2023Article
- The Role of MicroRNAs in Myocarditis-What Can We Learn from Clinical Trials?International journal of molecular sciences · 2022Review
- A curated human cellular microRNAome based on 196 primary cell types.GigaScience · 2022Article
- MicroRNAs as therapeutic targets in cardiovascular disease.The Journal of clinical investigation · 2022Review
- Hsa-miR-199a-5p Protect Cell Injury in Hypoxia Induces Myocardial Cells Via Targeting HIF1α.Molecular biotechnology · 2022Article
- Exosomal RNAs in diagnosis and therapies.Non-coding RNA research · 2022Article
- Exploring Endothelial Colony-Forming Cells to Better Understand the Pathophysiology of Disease: An Updated Review.Stem cells international · 2022Review
- MicroRNA expression profile and identification of novel microRNA biomarkers for metabolic syndrome.Bioengineered · 2021Article
- MicroRNA-24 protects against myocardial ischemia-reperfusion injury via the NF-κB/TNF-α pathway.Experimental and therapeutic medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Cardiovascular diseases exist across all developed countries. Biomarkers that can predict or diagnose diseases early in their pathogeneses can reduce their morbidity and mortality in afflicted individuals. microRNAs are small regulatory RNAs that modulate translation and have been identified as potential fluid-based biomarkers across numerous maladies. We describe the current state of cardiovascular disease biomarkers across a range of diseases, including myocardial infarction, acute coronary syndrome, myocarditis, hypertension, heart failure, heart transplantation, aortic stenosis, diabetic cardiomyopathy, atrial fibrillation, and sepsis. We present the current understanding of microRNAs as possible biomarkers in these categories and where their best opportunities exist to enter clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.